Bedossa P

16 publications in the catalogue · 1991–2025 · 2 as first author

16 publications

Diseases

  1. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025

    FibroTest-T2D Metabolic

  2. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  3. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022

    FibroTest Metabolic

  4. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021

    FibroTest NashTest-2 SteatoTest Metabolic

  5. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019

    FibroTest NashTest SteatoTest HIV

  6. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016

    ActiTest FibroTest SteatoTest Metabolic

  7. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015

    FibroTest HCV

  8. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012

    Metabolic

  9. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012

    ActiTest FibroTest NashTest SteatoTest +1

  10. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010

    FibroTest HBV HCV HIV

  11. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009

    FibroTest SteatoTest HBV HCV +1

  12. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007

    FibroTest Alcohol HBV HCV +1

  13. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997

    HCV

  14. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

    Bedossa P et al. · Hepatology · 1996

    HCV

  15. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.

    Naveau S et al. · Dig Dis Sci · 1994

    Alcohol

  16. A simple biological index for detection of alcoholic liver disease in drinkers.

    Poynard T et al. · Gastroenterology · 1991

    Alcohol